Vildagliptin 50 Mg (Generic)

Price range: 64.00$ through 160.00$

Product Overview Vildagliptin 50 mg is a prescription oral antidiabetic medication marketed by Cipla Limited under the generic name Vildagliptin. It is formulated for the management of type 2 diabetes mellitus in adults when diet and exercise alone a

Active Ingredients	Vildagliptin
Delivery Time	6 To 15 days
Indication	Type 2 diabetes
Manufacturer	Cipla Limited
Packaging	15 tablets in 1 strip
Strength	50mg

Estimated Delivery: Thu, Aug 13 – Sat, Aug 15

... people are viewing this right now

Guaranteed Safe Checkout

Pack Size	Price	Quantity
60 Tablet/s	64.00$
120 Tablet/s	98.00$
240 Tablet/s	160.00$

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

Vildagliptin 50 mg is a prescription oral antidiabetic medication marketed by Cipla Limited under the generic name Vildagliptin. It is formulated for the management of type 2 diabetes mellitus in adults when diet and exercise alone are insufficient to achieve glycemic control. The drug is supplied in a strip containing 15 immediate‑release tablets, each delivering 50 mg of the active ingredient. Pack size options include 60, 120, or 240 tablets, allowing patients and clinicians to select the most appropriate quantity based on treatment duration and insurance coverage.

What is Vildagliptin 50 Mg

Vildagliptin belongs to the class of dipeptidyl‑peptidase‑4 (DPP‑4) inhibitors, a group of agents that enhance the activity of incretin hormones such as GLP‑1 and GIP. By blocking the DPP‑4 enzyme, Vildagliptin prolongs the lifespan of these hormones, leading to increased insulin secretion from pancreatic β‑cells and decreased glucagon release from α‑cells, ultimately resulting in lower blood glucose levels. The 50 mg dosage is the standard strength for once‑daily oral administration in most adult patients with type 2 diabetes.

Uses and Benefits

The primary indication for Vildagliptin 50 mg is the improvement of glycemic control in adults with type 2 diabetes mellitus. Clinical studies have demonstrated that regular use of Vildagliptin, in combination with a healthy diet and regular physical activity, can reduce HbA1c levels by approximately 0.5 to 1.0 % over a 24‑week period. Additional benefits include weight neutrality, a low risk of hypoglycemia when used alone, and a favorable safety profile compared with some older sulfonylureas. The medication is also compatible with many other antidiabetic agents, making it a versatile option for combination therapy.

Patients often appreciate the convenience of a once‑daily tablet and the absence of frequent dosing adjustments. Moreover, Vildagliptin has been shown to preserve β‑cell function over time, which may contribute to a slower progression of the disease. For comprehensive patient education, reputable sources such as the MedlinePlus Diabetes Overview provide evidence‑based guidance on lifestyle and pharmacologic management.

How It Works

The pharmacodynamic action of Vildagliptin centers on the inhibition of the enzyme dipeptidyl‑peptidase‑4 (DPP‑4). DPP‑4 rapidly degrades incretin hormones (GLP‑1 and GIP) that are released from the gut after meals. By blocking this enzymatic activity, Vildagliptin prevents the breakdown of incretins, leading to prolonged stimulation of insulin secretion and suppression of glucagon release when glucose levels rise. This dual effect enhances glycemic control without causing a significant increase in insulin levels during fasting, thereby minimizing the risk of hypoglycemia. Detailed mechanistic data can be reviewed in peer‑reviewed literature, for example on PubMed.

Dosage Guidelines

Vildagliptin 50 mg is typically prescribed as one tablet taken orally once daily, with or without food. The dosage may be adjusted in patients with moderate to severe renal impairment (estimated glomerular filtration rate < 50 mL/min/1.73 m²), where a reduced dose of 25 mg once daily is recommended to avoid accumulation. It is essential to adhere strictly to the dosing schedule and not to exceed the prescribed amount. Missed doses should be taken as soon as remembered unless it is close to the time of the next dose; in such cases, the missed dose should be skipped and the regular schedule resumed. Consistency in timing helps maintain steady plasma concentrations and optimal glycemic control.

For detailed dosing recommendations, clinicians can refer to the official prescribing information available via the U.S. Food and Drug Administration (FDA) label database. Patients should always discuss any dose modifications with their healthcare provider before implementation.

Side Effects

Like all medications, Vildagliptin 50 mg can be associated with adverse effects. The most commonly reported side effects include mild gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea, which are usually transient and resolve without medical intervention. Less frequent but clinically important adverse events may involve upper respiratory infections, headache, or dizziness. Rarely, cases of pancreatitis have been reported; however, a direct causal relationship has not been established. Patients should be instructed to seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction such as rash, swelling, or difficulty breathing.

Comprehensive safety data can be accessed through the Drugs.com prescribing guide, which consolidates reported adverse events from clinical trials and post‑marketing surveillance.

Warnings and Precautions

Before initiating therapy with Vildagliptin 50 mg, healthcare providers should assess renal function, hepatic function, and history of pancreatitis. The medication is contraindicated in patients with a known hypersensitivity to Vildagliptin or any of the excipients in the formulation. Caution is advised in individuals with a history of chronic kidney disease, as dose adjustment may be necessary. Additionally, Vildagliptin should be used with care in patients taking strong CYP3A4 inducers or inhibitors, as these agents can alter drug levels. Pregnant or breastfeeding women should only use Vildagliptin if the potential benefits outweigh the risks, and a discussion with a qualified clinician is recommended.

For official contraindication and precaution details, refer to the Wikipedia entry on Vildagliptin, which summarizes key safety considerations derived from regulatory submissions.

Frequently Asked Questions

Can Vildagliptin be used alongside metformin?
Yes, Vildagliptin is frequently prescribed in combination with metformin, sulfonylureas, or insulin when additional glycemic control is required. However, the prescribing clinician must evaluate potential drug interactions and adjust doses as needed.
How long does it take to see a reduction in HbA1c?
Clinical studies indicate that a measurable decrease in HbA1c can be observed after 12 to 24 weeks of consistent daily use, although individual response may vary based on baseline glucose levels and adherence.
Is weight gain a common side effect?
Weight gain is not typically associated with Vildagliptin. Most patients experience weight neutrality, making it a favorable option for those concerned about weight fluctuations.
What should I do if I miss a dose?
If a dose is missed, take it as soon as you remember unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule; do not double up on doses.
Are there any dietary restrictions while taking Vildagliptin?
No specific dietary restrictions are required. Patients should maintain a balanced diet and engage in regular physical activity to optimize glycemic control, but Vildagliptin can be taken with or without food.